Agitation in Alzheimer’s disease represents a complex neuropsychiatric syndrome with distinct biological underpinnings that extend beyond the amyloid and tau pathology traditionally associated with cognitive decline.1,2 Recent neuroimaging and neurochemical studies demonstrate that agitation correlates with specific patterns of regional brain dysfunction, particularly involving frontal-subcortical circuits and neurotransmitter system dysregulation.1,3 Understanding these mechanistic drivers creates opportunities for more precise therapeutic targeting and personalized treatment approaches.1
Serotonergic pathway dysfunction has emerged as a central mediator of agitation in dementia, with selective serotonin reuptake inhibitors used in chronic agitation.1 The serotonin 5-HT2A receptor appears particularly relevant for dementia-related psychosis, with altered receptor density and function contributing to dysregulated emotional processing and behavioral disinhibition.4 These findings support the rationale for pharmacologic interventions that modulate serotonergic neurotransmission, including agents with inverse agonist activity at 5-HT2A receptors.4
Noradrenergic system alterations also contribute to agitation pathophysiology. Locus coeruleus degeneration, which occurs early in Alzheimer’s disease progression, disrupts norepinephrine-mediated regulation of arousal, attention, and stress response.5 This dysfunction may manifest as hyperarousal states, emotional lability, and exaggerated responses to environmental stimuli.5 Dopaminergic pathway involvement further complicates the neurotransmitter landscape, with evidence suggesting that dopamine receptor modulation influences both motor and behavioral manifestations of agitation.6
Advanced neuroimaging techniques have identified structural and functional correlates of agitation distinct from those associated with cognitive impairment alone.7 Volumetric analyses demonstrate associations between agitation severity and atrophy in the bilateral anterior cingulate cortex and left dorsolateral prefrontal cortex.7 These findings support the concept that agitation represents a specific neurobehavioral phenotype with identifiable neural circuit abnormalities rather than a nonspecific consequence of global neurodegeneration.
The therapeutic implications of these mechanistic insights extend beyond symptom management to consideration of targeted interventions based on individual patient neurobiology. Pharmacologic strategies that address specific neurotransmitter system dysfunction, including combined serotonin receptor modulation and dopamine receptor partial agonism, offer a new mechanistically targeted approach designed to address underlying pathophysiology.8 Treatment selection increasingly incorporates assessment of symptom profiles, comorbid conditions, and potential risks to optimize the balance between symptom control and adverse effect burden.9
Take our agitation in Alzheimer’s disease quiz to see how your knowledge compares to your peers.
